Loading...
Loading...
VRPX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 1,651.1K |
| Operating I/L | -1,651.1K |
| Other Income/Expense | 130.5K |
| Interest Income | 0.0K |
| Pretax | -1,520.5K |
| Income Tax Expense | -130.5K |
| Net Income/Loss | -1,390.0K |
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company specializing in non-opioid and non-addictive pain management treatments and central nervous system disorder therapies. The company develops drug-delivery systems and drug-releasing technologies, with a focus on products such as Epoladerm, Probudur, and Envelta for chronic osteoarthritis, postoperative pain, and intranasal drug delivery. Additionally, their product pipeline includes PES200, AnQlar, and VRP324, targeting brain drug delivery, anti-viral barriers, and enhanced cannabidiol transport. Virpax Pharmaceuticals generates revenue through the development and potential commercialization of these innovative pharmaceutical products.
